<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967433</url>
  </required_header>
  <id_info>
    <org_study_id>DAASIPCO</org_study_id>
    <nct_id>NCT01967433</nct_id>
  </id_info>
  <brief_title>Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids</brief_title>
  <official_title>Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To access the efficacy of adding diphenhydramine as adjunct to improve sedation and to reduce
      the amount of standard sedatives used during colonoscopy in patients on chronic opioids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

      The primary aim of our study is to determine if addition of Diphenhydramine to Fentanyl and
      Midazolam will decrease the dose of Fentanyl and Midazolam used during colonoscopy in
      individuals on chronic opioids. Secondarily we will be looking at quality of sedation,
      duration of colonoscopy, time to reach cecum and adverse effects (hypoxia defined as O2
      saturation less than 89% lasting for more than 30 seconds, hypotension defined as systolic BP
      less than 90 mmhg and use of reversal agents i.e Naloxone or Flumazenil).

      Day of Procedure:

      After consent is obtained the medical records of the patients will be reviewed and
      demographic information, co-morbidities, current medication will be extracted and recorded.

      On the day of colonoscopy Alcohol use disorder inventory (AUDIT) will be used to screen for
      alcohol abuse. AUDIT was developed by World Health Organization and has been validated over a
      period of 2 decades. It consist of 10 questions, each question is scored 0-4 on the basis of
      subjects alcohol use. It takes about 2-4 minutes to complete. A score 10 or greater is highly
      specific or alcohol use.

      Subjects will be checked in and prepared according to routine protocols of the VA medical
      center. Participants will be randomly assigned to receive either 50 mg of diphenhydramine or
      10 ml of 0.9% sodium chloride. On the day of colonoscopy randomization will be performed by
      an independent investigator who is a pharmacist at VA medical center using the website
      http://www.randomization.com. She will also prepare and dispense medication. Each endoscopy
      team will consist of an attending gastroenterologist, gastroenterology fellow and two nurses.
      Medications will be administered by one of the nurses under the direct supervision of the
      physician.

      At the start of procedure baseline vitals will be recorded as per our unit's policy. Research
      medication will be administered 3 minutes prior to administration of other medications.
      Neither the patient nor the medical staff including the endoscopist will be aware of the
      contents of the vial. Conscious sedation will be achieved using a combination of intravenous
      midazolam and fentanyl as standard sedative. Rarely, additional diphenhydramine will be
      given, on the basis of the judgment of the endoscopist. During the procedure vital signs
      including oxygen saturation will be monitored at 3-5 minute interval. Procedure related
      complications, including hypotension, desaturation and cardiac arrhythmia will be managed
      according to our endoscopy unit policy and protocols.

      Following the procedure, the nurse and the fellow or the attending will individually rate the
      quality if sedation on a ten-point Likert scale. Qualitative assessment will also be made
      (Under-sedated, adequately sedated, or over-sedated).

      Recovery time will be recorded.

      Day Following the Colonoscopy Twenty-four hour discharge a follow up call will be made and
      the patients will be asked to evaluate the level of sedation on a 10-point scale (1,
      inadequate; 10 completely without discomfort); pain (1, no pain; 10 severe pain), and amnesia
      (10, no memory of the procedure; 1 complete memory).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of Fentanyl and Midazolam</measure>
    <time_frame>Within 30 minutes of completion of colonoscopy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of sedation</measure>
    <time_frame>During the colonoscopy and 24 hours after discharge</time_frame>
    <description>Quality of sedation will be accessed by the nurse and the physician at the end of procedure. Patient will be asked to rate pain, sedation and amnesia on a 10 point scale 24 after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Procedure</measure>
    <time_frame>Within 30 minutes of completion of colonoscopy</time_frame>
    <description>Total time and time to reach cecum will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During the colonoscopy and within 1 hour of completion of colonoscopy</time_frame>
    <description>Following adverse events will be recorded: (1)Hypoxia defined as O2 saturation less than 89% lasting for more than 30 seconds, (2)hypotension defined as systolic BP less than 90 mmhg and (3)use of reversal agents i.e Naloxone or Flumazenil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour follow up</measure>
    <time_frame>About 24 hours after the procedure</time_frame>
    <description>Patient will be asked to rate the level of pain, amnesia and quality of sedation during the procedure using 10 point scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Adjunct Anesthesia Medication</condition>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-64 years undergoing screening, surveillance, diagnostic and
             therapeutic colonoscopy

          -  Patient on chronic opioids defined as at least 5 mg of morphine or its equivalent at
             least 3 days per week for more than 3 months

        Exclusion Criteria:

          -  Inability to execute informed consent

          -  Allergy to Diphenhydramine, fentanyl or midazolam

          -  Known or suspected pregnancy

          -  Endoscopic procedure without sedation

          -  Patient scheduled to have other endoscopic procedures on the same day

          -  Prior alimentary tract surgery

          -  Severe cardiopulmonary disease (ASA IV)

          -  MOI use within 2 weeks of procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salman Nusrat, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Madhoun, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Oklahoma Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost-outcome study. Am J Gastroenterol. 2004 Sep;99(9):1692-9.</citation>
    <PMID>15330904</PMID>
  </reference>
  <reference>
    <citation>Zubarik R, Ganguly E, Benway D, Ferrentino N, Moses P, Vecchio J. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. Am J Gastroenterol. 2002 Dec;97(12):3056-61.</citation>
    <PMID>12492190</PMID>
  </reference>
  <reference>
    <citation>Bergeron P, Enns J, Delima L, Dupuis JY, Wynands JE. Effects of routine premedication for cardiac catheterization on sedation, level of anxiety and arterial oxygen saturation. Can J Cardiol. 1995 Mar;11(3):201-5.</citation>
    <PMID>7889437</PMID>
  </reference>
  <reference>
    <citation>Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. Br Med J (Clin Res Ed). 1984 Aug 11;289(6441):351-3.</citation>
    <PMID>6432093</PMID>
  </reference>
  <reference>
    <citation>Pe√±a LR, Mardini HE, Nickl NJ. Development of an instrument to assess and predict satisfaction and poor tolerance among patients undergoing endoscopic procedures. Dig Dis Sci. 2005 Oct;50(10):1860-71.</citation>
    <PMID>16187188</PMID>
  </reference>
  <reference>
    <citation>Keeffe EB, O'Connor KW. 1989 A/S/G/E survey of endoscopic sedation and monitoring practices. Gastrointest Endosc. 1990 May-Jun;36(3 Suppl):S13-8.</citation>
    <PMID>2351253</PMID>
  </reference>
  <reference>
    <citation>Hirsh I, Vaissler A, Chernin J, Segol O, Pizov R. Fentanyl or tramadol, with midazolam, for outpatient colonoscopy: analgesia, sedation, and safety. Dig Dis Sci. 2006 Nov;51(11):1946-51. Epub 2006 Sep 29.</citation>
    <PMID>17009113</PMID>
  </reference>
  <reference>
    <citation>Tu RH, Grewall P, Leung JW, Suryaprasad AG, Sheykhzadeh PI, Doan C, Garcia JC, Zhang N, Prindiville T, Mann S, Trudeau W. Diphenhydramine as an adjunct to sedation for colonoscopy: a double-blind randomized, placebo-controlled study. Gastrointest Endosc. 2006 Jan;63(1):87-94.</citation>
    <PMID>16377322</PMID>
  </reference>
  <reference>
    <citation>Roach CL, Husain N, Zabinsky J, Welch E, Garg R. Moderate sedation for echocardiography of preschoolers. Pediatr Cardiol. 2010 May;31(4):469-73. doi: 10.1007/s00246-009-9622-z. Epub 2010 Jan 3.</citation>
    <PMID>20047024</PMID>
  </reference>
  <reference>
    <citation>Hofmeister EH, Egger CM. Evaluation of diphenhydramine as a sedative for dogs. J Am Vet Med Assoc. 2005 Apr 1;226(7):1092-4.</citation>
    <PMID>15825733</PMID>
  </reference>
  <reference>
    <citation>Husain Z, Hussain K, Nair R, Steinman R. Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug. Cardiol J. 2010;17(5):509-11.</citation>
    <PMID>20865683</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fentanyl</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Sedation</keyword>
  <keyword>Patient tolerance</keyword>
  <keyword>Duration of colonoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

